Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurotech Pharmaceuticals, Inc. Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase III"},{"orgOrder":0,"company":"Neurotech Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Neurotech Receives Priority Review for NT-501 as Treatment for MacTel Type 2","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2024","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Phase III"}]

    Find Clinical Drug Pipeline Developments & Deals by Neurotech Pharmaceuticals

    Menu

    Neurotech Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Neurotech Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neurotech Receives Priority Review for NT-501 as Treatment for MacTel Type 2

              Details:

              NT-501 (revakinagene taroretcel) leverages is a gene therapy which delivers CNTF through an ocular implant, it is designed for the treatment of chronic retinal diseases, such as MacTel.

              Lead Product(s): Revakinagene Taroretcel

              Therapeutic Area: Rare Diseases and Disorders Product Name: NT-501

              Highest Development Status: Phase III Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 20, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Neurotech Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Neurotech Pharmaceuticals, Inc. Announces Positive Phase 3 Topline Results for NT-501 Implant in Macular Telangiectasia Type 2

              Details:

              Designed to be implanted into the vitreous cavity of the eye, the investigational Ciliary Neurotrophic Factor(Renexus) implant is a tiny hollow cylindrical membrane which encapsulates human epithelial cells genetically engineered to produce CNTF continuously.

              Lead Product(s): Ciliary Neurotrophic Factor

              Therapeutic Area: Ophthalmology Product Name: Renexus

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 02, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY